Exicure Virtual KOL Event 2020

Virtual, September 16, 2020

Exicure to discuss the preliminary Phase 1b safety and efficacy data for cavrotolimod, Exicure’s SNA-enabled TLR9 agonist for solid tumors.Principal Investigators Dr. Steven J. O’Day and Dr. Shailender Bhatia will join Exicure’s leadership team in discussing clinical progress to date.

Dr.-Steven-ODay_lab-coat-480x480_cd596s.jpg    Steven J. O’Day, MD, is the Executive Director of the John Wayne Cancer Institute and Cancer Clinic, and Director of Providence Los Angeles Regional Research. He is the Professor of Medical Oncology, Director of Immuno-Oncology, and Director of Clinical Research at the John Wayne Cancer Institute at Providence Saint John’s Health Center.  
   
Shailender_Bhatia_Hero_gedb64.jpg
 
Shailender Bhatia, MD, is an Associate Professor at the University of Washington School of Medicine and an Assistant Professor of the Clinical Research Division at the Fred Hutchinson Cancer Research Center.
RSVP for Event / Log Back in

Additional menu options can be found in the menu bar on the left or at the top.

Exicure [XCUR] US$161 MM MCap
Cavro­toli­mod (AST-008) in Ph2 trials for pa­tients with Merkel Cell Car­ci­no­ma and Cu­ta­neous Squa­mous Cell Car­ci­no­ma, with Ph1b da­ta pre­sent­ed at AACR 2020. XCUR-FXN in pre­clin­i­cal de­vel­op­ment for pa­tients with Frie­dreich's Ataxia, us­ing ge­net­i­cal­ly tar­get­ed SNA ther­a­pies to re­move FXN tran­scrip­tion block­age, with IND ex­pect­ed in late 2020. [more in­for­ma­tion]

Event Contact

Rebecca John
Solebury Trout